Lipocine price target raised to $11 from $6.75 at Alliance Global

Alliance Global raised the firm’s price target on Lipocine (LPCN) to $11 from $6.75 and keeps a Buy rating on the shares. Q4 earnings were within the range of expectations, says the analyst, who cites a higher estimated probability of approval for LPCN 1154 and lower expected dilution for the firm’s raised target. The LPCN 1154 post-partum depression trial is on track for a readout early this April, notes the analyst, who is “encouraged” by the safety data from the January DSMB review.